Skip to Main Content


The small-molecule agents discussed in this chapter—aminoglycosides, polymyxins, and urinary antiseptics—primarily target gram-negative bacteria and have a limited set of clinical applications due to their toxicities and pharmacokinetic properties. Additionally, we discuss the (re-)emerging application of phages in infectious diseases therapeutics.



AC: acetylase

AD: adenylase

AUC: area under the curve

CMS: colistin methanesulfonate

CNS: central nervous system

CsCl: cesium chloride

CSF: cerebrospinal fluid

FDA: Food and Drug Administration

G6PD: glucose-6-phosphate dehydrogenase

GI: gastrointestinal

IM: intramuscular

IV: intravenous

MIC: minimal inhibitory concentration

mRNA: messenger RNA

PFU: plaque-forming units

PO: by mouth

UTI: urinary tract infection



Aminoglycosides are natural products or semisynthetic derivatives of compounds produced by a variety of soil actinomycetes. Streptomycin was first isolated from a strain of Streptomyces griseus. Gentamicin and netilmicin are derived from species of the actinomycete Micromonospora. The difference in spelling (-micin) compared with the other aminoglycoside antibiotics (-mycin) reflects this difference in origin. Tobramycin is one of several components of an aminoglycoside complex known as “nebramycin” that is produced by Streptomyces tenebrarius. It is most similar in antimicrobial activity and toxicity to gentamicin. In contrast to the other aminoglycosides, amikacin (a derivative of kanamycin) and netilmicin and plazomicin (derivatives of sisomicin) are semisynthetic products.

Aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin, plazomicin, kanamycin, streptomycin, paromomycin, and neomycin) are used primarily to treat infections caused by aerobic gram-negative bacteria. Streptomycin and amikacin are important agents for the treatment of mycobacterial infections, and paromomycin is used orally for intestinal amebiasis. Aminoglycosides are bactericidal inhibitors of protein synthesis. Most commonly, resistance is due to aminoglycoside-modifying enzymes or impaired accumulation of drug at the target site; these mechanisms may confer resistance to all aminoglycosides or only select agents. Resistance genes are frequently acquired via plasmids or transposons.

Aminoglycosides contain amino sugars linked to an aminocyclitol ring by glycosidic bonds (Figure 59–1). They are polycations, and their polarity is responsible in part for pharmacokinetic properties shared by all members of the group. For example, none is absorbed adequately after oral administration, inadequate concentrations are found in CSF, and all are excreted relatively rapidly by the normal kidney. All members of the group share the same spectrum of toxicity, most notably nephrotoxicity and ototoxicity, which can involve the auditory and vestibular functions of the eighth cranial nerve, although the relative propensities for toxicity vary somewhat among the agents.

Figure 59–1

Aminoglycoside structure and sites of activity of plasmid-mediated enzymes capable of inactivating aminoglycosides. Tobramycin is shown as a representative; structural characteristics protect some aminoglycosides from the actions of some of these enzymes, explaining differences in spectrum of activity. AC, acetylase; AD, adenylase.

Mechanism of Action


Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.